Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Primary Care Management Pathways to Reduce Wait Times in Hematology: Monoclonal Gammopathy of Undetermined Significance

Pallavi Ganguli, Janique Dyba, Annette E. Hay, Liying Zhang, Samuel A Silver, Yun Huang, Kevin Loughlin, Elizabeth Eisenhauer, Bethany Elaine Monteith

Blood (2023) 142 (Supplement 1): 908.

https://doi.org/10.1182/blood-2023-179080

Published: 2023

Journal Articles

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Rena Buckstein, MD, John Kuruvilla, MD, Neil Chua, MD, Christina Lee, David A Macdonald, MD, Abdulwahab J. Al-Tourah, MD, Alison Foo, Wendy Walsh, S. Percy Ivy, MD, Michael Crump, MD, Elizabeth Eisenhauer, MD

Blood (2009) 114 (22): 2729.

https://doi.org/10.1182/blood.V114.22.2729.2729

Published: 2009

Journal Articles

Phase II Trial of Bortezomib in Mantle Cell Lymphoma.

Andrew Belch, FRCPC, C. Tom Kouroukis, Michael Crump, Laurie Sehn, Randy Gascoyne, Richard Klasa, Powers Jean, Elizabeth Eisenhauer

Blood (2004) 104 (11): 608.

https://doi.org/10.1182/blood.V104.11.608.608

Published: 2004

Journal Articles

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

Christine I. Chen, MD, Darrell White, MD, C. Tom Kouroukis, MD, A. Keith Stewart, MD, Kang Howson-Jan, MD, Loree Larratt, MD, Jean Powers, Elizabeth Eisenhauer, MD

Blood (2004) 104 (11): 3278.

https://doi.org/10.1182/blood.V104.11.3278.3278

Published: 2004

Journal Articles

A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).

Michael J. Kovacs, MD, FRCPC, Donna E. Reece, MD, FRCPC, Deborah Marcellus, MD, Ralph M. Meyer, MD, Sarah Matthews, MSc, Rui-Ping Dong, MD, PhD, Elizabeth Eisenhauer, MD, FRCPC

Blood (2004) 104 (11): 3464.

https://doi.org/10.1182/blood.V104.11.3464.3464

Published: 2004

Journal Articles

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Ian W. Flinn, Kenneth J. Kopecky, M. Kathryn Foucar, David Head, John M. Bennett, Robert Hutchison, William Corbett, Peter Cassileth, Thomas Habermann, Harvey Golomb, Kanti Rai, Elizabeth Eisenhauer, Frederick Appelbaum, Bruce Cheson, Michael R. Grever

Blood (2000) 96 (9): 2981–2986.

https://doi.org/10.1182/blood.V96.9.2981

Published: 2000

NARROW

Primary Care Management Pathways to Reduce Wait Times in Hematology: Monoclonal Gammopathy of Undetermined Significance

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Phase II Trial of Bortezomib in Mantle Cell Lymphoma.

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Email alerts

ASH Publications

American Society of Hematology

Primary Care Management Pathways to Reduce Wait Times in Hematology: Monoclonal Gammopathy of Undetermined Significance

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Phase II Trial of Bortezomib in Mantle Cell Lymphoma.

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only